Markov state modelling reveals heterogeneous drug-inhibition mechanism of Calmodulin

PLoS Comput Biol. 2022 Oct 7;18(10):e1010583. doi: 10.1371/journal.pcbi.1010583. eCollection 2022 Oct.

Abstract

Calmodulin (CaM) is a calcium sensor which binds and regulates a wide range of target-proteins. This implicitly enables the concentration of calcium to influence many downstream physiological responses, including muscle contraction, learning and depression. The antipsychotic drug trifluoperazine (TFP) is a known CaM inhibitor. By binding to various sites, TFP prevents CaM from associating to target-proteins. However, the molecular and state-dependent mechanisms behind CaM inhibition by drugs such as TFP are largely unknown. Here, we build a Markov state model (MSM) from adaptively sampled molecular dynamics simulations and reveal the structural and dynamical features behind the inhibitory mechanism of TFP-binding to the C-terminal domain of CaM. We specifically identify three major TFP binding-modes from the MSM macrostates, and distinguish their effect on CaM conformation by using a systematic analysis protocol based on biophysical descriptors and tools from machine learning. The results show that depending on the binding orientation, TFP effectively stabilizes features of the calcium-unbound CaM, either affecting the CaM hydrophobic binding pocket, the calcium binding sites or the secondary structure content in the bound domain. The conclusions drawn from this work may in the future serve to formulate a complete model of pharmacological modulation of CaM, which furthers our understanding of how these drugs affect signaling pathways as well as associated diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / chemistry
  • Binding Sites
  • Calcium / metabolism
  • Calmodulin* / metabolism
  • Protein Binding
  • Trifluoperazine / chemistry
  • Trifluoperazine / metabolism
  • Trifluoperazine / pharmacology

Substances

  • Calmodulin
  • Trifluoperazine
  • Antipsychotic Agents
  • Calcium

Grants and funding

AMW was funded by a Swedish e-research center (SeRC) COVID-19 transition grant. AS was funded by Marie-Sklodowska Curie Fellowship Lipopeutics (Grant Number 898762). LDe acknowledges the Science for Life Laboratory (SciLifeLab), the Göran Gustafsson foundation and the Swedish Research Council (VR 2018-04905 and 2019-02433) for funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.